The tumor-suppressor gene PTEN encodes a multifunctional phosphatase that is mutated in a variety of human cancers. PTEN inhibits the phosphatidylinositol 3-kinase pathway and downstream functions, including activation of Akt/protein kinase B (PKB), cell survival, and cell proliferation in tumor cells carrying mutant-or deletion-type PTEN. In such tumor cells, enforced expression of PTEN decreases cell proliferation through cell-cycle arrest at G1 phase accompanied, in some cases, by induction of apoptosis. More recently, the tumor-suppressive effect of PTEN has been reported in ovarian and thyroid tumors that are wild type for PTEN. In the present study, we examined the tumor-suppressive effect of PTEN in human colorectal cancer cells that are wild type for PTEN. Adenoviral-mediated transfer of PTEN (Ad-PTEN) suppressed cell growth and induced apoptosis significantly in colorectal cancer cells (DLD-1, HT29, and SW480) carrying wtPTEN than in normal colon fibroblast cells (CCD-18Co) carrying wtPTEN. This suppression was induced through downregulation of the Akt/PKB pathway, dephosphorylation of focal adhesion kinase (FAK) and mitogen-activated protein kinase (MAPK) and cell-cycle arrest at the G2/M phase, but not the G1 phase. Furthermore, treatment of human colorectal tumor xenografts (HT-29, and SW480) with Ad-PTEN resulted in significant (P¼0.01) suppression of tumor growth. These results indicate that Ad-PTEN exerts its tumorsuppressive effect on colorectal cancer cells through inhibition of cell-cycle progression and induction of cell death. Thus Ad-PTEN may be a potential therapeutic for treatment of colorectal cancers.
Introduction
PTEN is a tumor-suppressor gene located on human chromosome 10q23.3.
1,2 Deletion and somatic mutation of PTEN occur frequently in glioblastoma, endometrial cancer, prostate cancer, and small-cell lung cancer. [3] [4] [5] [6] [7] Furthermore, germline mutations of PTEN are the cause of Cowden disease and Bannayan-Zonana syndrome, which are autosomal dominant cancer predisposition disorders. [8] [9] [10] PTEN functions as both a protein and lipid phosphatase in cells that are genotypically wild type for PTEN. 11, 12 The former activity consists of dephosphorylation of focal adhesion kinase (FAK) and Shc, which are upstream of the p44/42 mitogen-activated protein kinase (MAPK) pathway associated with the inhibition of cell spreading and migration, 13, 14 while the latter activity consists of dephosphorylation of phosphatidylinositoltriphosphate (PtdIns (3,4,5)P3) and phosphatidylinositolbiphosphate (PtdIns (3,4)P2). 11 PTEN also modulates the phosphatidylinositol 3-kinase (PI3K) pathway by catalyzing degradation of PtdIns (3, 4, 5) P3 generated by PI3K. This mechanism inhibits downstream functions mediated by the PI3K pathway, such as activation of Akt/protein kinase B (PKB), cell survival, and cell proliferation. 15 Thus, overexpression of PTEN in cancer cells carrying mutant-or deletion-type PTEN can inhibit cell proliferation and tumorigenicity via induction of cell-cycle arrest at G1 phase and apoptosis. [16] [17] [18] [19] Although studies demonstrating the inhibitory function of PTEN in tumor cells mutant for PTEN exist, very little information is available on the effect of PTEN in tumor cells that are wild-type for PTEN (wtPTEN). More recently, studies using colorectal, ovarian, and thyroid cancer cells that are wtPTEN, demonstrated ectopic expression of PTEN resulting in growth inhibition and cell death. [20] [21] [22] Based on these reports, we investigated the tumor-suppressive effect of PTEN in colorectal cancer cells that are wtPTEN.
In the present study, we demonstrate that adenovirusmediated overexpression of PTEN (Ad-PTEN) in colorectal cancer cells and in normal colon fibroblast cells that are wtPTEN results in selective induction of G2 cell-cycle arrest and apoptosis in tumor cells, but not in normal cells. Furthermore, treatment of colorectal tumor xenografts with Ad-PTEN resulted in tumor inhibition. These results indicate that Ad-PTEN can be used as a gene therapeutic for the treatment of colorectal cancers.
Results
Inhibition of cell proliferation in colorectal cancer due to overexpression of PTEN Tumor cells (DLD-1, SW480, HT29, and Colo 320 HSR) and normal cells (CCD-18Co) were treated with PBS, AdLuc, or Ad-PTEN and examined for exogenous PTEN expression and cell proliferation at various time points. Treatment with Ad-PTEN resulted in exogenous PTEN expression in all the cell lines tested (Figure 1a) . However, endogenous PTEN expression was also observed in all the cell lines, indicating that they are wild type for PTEN, except Colo 320 HSR that is mutant for PTEN. Although Colo 320 HSR cell line is mutant for PTEN, detection of PTEN protein is not surprising since it has been previously reported to produce a truncated PTEN protein that lacks the tumor-suppressive activity. 23 Furthermore, analysis for cell viability daily on days 1-5 demonstrated significant inhibition of cell proliferation (Po0.01) in all the cancer cell lines treated with Ad-PTEN, when compared with that in control cells treated with Ad-Luc or treated with PBS ( Figure 1b) . In normal cells (CCD-18Co), Ad-PTEN treatment resulted in moderate inhibition of cell growth compared to cells treated with Ad-Luc and PBS (Figure 1b) . However, Ad-PTEN-mediated inhibitory effect on tumor cell proliferation was greater and more pronounced than that observed in normal cells. Minimal to no inhibitory effect on cell proliferation was also observed in normal human colon epithelial cell line (FHC) when treated with Ad-PTEN (data not shown). These results suggest that Ad-PTEN may selectively and more effectively inhibit tumor cells than normal cells.
Induction of apoptosis in colorectal cancer cells due to overexpression of PTEN
After treatment with Ad-PTEN, tumor cells (DLD-1, SW480, HT29, and Colo 320 HSR) and normal cells (CCD-18Co) were analyzed for apoptotic changes using fluorescence-activated cell sorter (FACS) and/or Hoechst 33258 staining. At 72 h after Ad-PTEN treatment, an increase in the number of cells in the sub-G0/G1 phase, an indicator of apoptotic changes, was observed in the four cancer cell lines by FACS analysis (Figure 2a) . The percent increase in apoptotic cells was between 5 and 35%, depending on the tumor cell type. However, no changes were observed in tumor cells treated with AdLuc or PBS. In contrast, no significant induction of apoptosis was observed in normal cells treated with Ad-PTEN compared to cells treated with PBS and Ad-Luc Induction of G2/M cell-cycle arrest due to overexpression of PTEN To determine whether Ad-PTEN is capable of inducing G1 cell-cycle arrest as previously reported, 21, 22, 24, 25 cell-cycle phases were analyzed using a fluorescenceactivated cell sorter (FACS). Cell-cycle analysis demonstrated an increase in the percentage (20-42%) of tumor Ad-PTEN did not induce G1 arrest in cancer cells carrying wtPTEN. To confirm that the Ad-PTEN-induced G2 arrest observed in wtPTEN cells was true and not due to experimental conditions used in the present study, we examined the effects of Ad-PTEN in cancer cells (Colo 
Signaling pathways modulated by PTEN overexpression in colorectal cancer cells
To determine the signaling pathways that are modulated by PTEN, we examined the expression of Akt, forkhead homolog of rhabdomyosarcoma (FKHR), and glycogen synthase kinase-3a/b (GSK-3a/b), which are downstream of the Akt kinase pathway and transcriptional regulators leading to apoptotic cell death, [27] [28] [29] in tumor cells (DLD-1) and normal cells (CCD-18Co) by Western blot analysis ( Figure 5 ). In DLD-1 cells, phospho-Akt was strongly dephosphorylated by Ad-PTEN and LY294002 (Figure 5a) . Surprisingly, increased phosphorylation of Akt was observed in cells treated with Ad-Luc. Also, phospho-FKHR (pFKHR) and phospho-GSK3a (pGSK3a), but not GSK-3b (pGSK-3b), were dephosphorylated significantly in DLD-1 cells by Ad-PTEN as compared with LY294002 and other controls ( Figure  5a ). In contrast, no significant change in pAkt, pFKHR, pGSK3a, and pGSK-3b was observed in Ad-PTENtreated CCD-18Co cells compared to control cells ( Figure  5b ). These results demonstrate that PTEN downregulates the Akt-kinase pathway and suppressed cell growth and proliferation in cancer cells, but not in normal cells carrying wtPTEN
We next examined the phosphorylation status of FAK (pFAK) and p44/42 MAPK associated with cell migration and/or focal adhesions in DLD-1 and CCD-18Co cells 72 h after infection. 13, 14, 30, 31 In DLD-1 cells, pFAK and p44/42 MAPK were dephosphorylated by Ad-PTEN, but not by Ad-Luc or PBS (Figure 5a ). U0126, which is an MEK 1/2 inhibitor, also inhibited p44/42 MAPK and served as a positive control. No changes in pFAK and p44/42 MAPK expression were observed in Ad-PTEN-treated CC18-Co cells compared to cells treated with Ad-Luc and PBS (Figure 5b ). These results demonstrate that PTEN can selectively inhibit cell migration and adhesion through downregulation of the FAK and MAPK pathways in cancer cells carrying wtPTEN, but not in normal cells.
Association of G2 arrest in cancer cells with downregulation of Cdc25C
To investigate the mechanisms through which Ad-PTEN induces G2/M arrest in cells carrying wtPTEN, we evaluated proteins related to the G2/M cell-cycle checkpoint using Western blot analysis. In this analysis, DLD-1 and CCD-18C0 cells were exposed to LY294002 or treated with Ad-PTEN or Ad-Luc. Total cell lysates were prepared 72 h after exposure or treatment and analyzed. DLD-1 and CCD-18Co cells treated with Ad-PTEN demonstrated reduced expression of both phosphorylated and nonphosphorylated Cdc25C and increased expression of cyclin B1 compared with that in cells that were treated with PBS or treated with Ad-Luc (Figure 6a,  b) . However, the inhibition of phospho-Cdc25C and total Cdc25C was more significant in DLD-1 cells than in CCD-18Co cells. These results indicate that Cdc25C may have been strongly phosphorylated by PTEN in tumor cells and then excluded from the nucleus through binding with 14-3-3 protein, 32, 33 resulting in a reduction of the amount of Cdc25C. Treatment with LY294002 showed no changes in the level of Cdc25C and cyclin B1 expression. These results are consistent with those of FACS analysis, which showed a significant induction of G2/M arrest caused by PTEN in tumor cells than in normal cells, while the PI3K inhibitor LY294002 induced G1 arrest.
Inhibition of colorectal tumor xenografts by PTEN
The ability of Ad-PTEN to inhibit subcutaneous tumor xenografts was evaluated next. Subcutaneous colorectal tumor xenografts established in nude mice were divided into groups (n¼9/group) and treated as follows: Group 1 received PBS, Group 2 received Ad-Luc, and Group 3 received Ad-PTEN. Intratumoral injections of Ad-PTEN on HT29 and SW480 tumor xenografts resulted in a significant (P¼0.01) growth inhibition compared to control tumors that were treated with PBS or treated with Ad-Luc (Figure 7a, b) . However, no complete tumor 
Discussion
In the present study, we investigated the effects of overexpressing PTEN protein in colorectal cancer cells that are wtPTEN. Prior to the start of the study, we examined the mutational status for PTEN gene in the cancer cell lines used in the study. Genetic alterations were determined by sequencing the coding region using exon-specific primers. All of the cancer cell lines, except Colo 320 HSR and CCD18-Co, were sequenced and found to contain no mutations in this gene (data not shown). The Colo 320 HSR cell line has recently been shown to have a 1-bp insertion in exon 7 of the PTEN gene resulting in a nonsense mutation. 23 As a consequence of the nonsense mutation, a truncated PTEN protein is produced that lacks the COOH-terminal region critical for the tumor-suppressive activity. The importance of the COOH-terminal region for the tumorsuppressive activity of the PTEN protein is well established. 34 Correlating with these results was the detection of exogenous PTEN protein expression in all the tumor and normal cells used in the present study. However, as described above, the PTEN protein detected in Colo 320 HSR cells lacks the tumor-suppressive activity. Furthermore, we showed that overexpression of PTEN suppresses the growth and induces apoptosis in colorectal cancer cell lines significantly compared to normal cells. These results are similar to the findings previously reported in colorectal, ovarian, and thyroid cancer that are wtPTEN. 20 ,21,22 However, one major difference observed in our results from others is that we observed that colorectal tumor cells that are wtPTEN were arrested in G2/M phase after Ad-PTEN treatment.
In contrast, previous studies have reported that ectopic expression of PTEN in cancer cells resulted in G1 arrest that was associated with an increase in p27 expression. 17, 18, 21, [35] [36] [37] Analysis for p27 expression in colorectal cancer cells after Ad-PTEN treatment demonstrated no change in expression levels (data not shown). In support of our findings is the recent report by Stewart et al, 38 who demonstrated enforced expression of PTEN-inhibited growth of melanoma cells that are wtPTEN. The discrepancy in the results is not clear. However, one possibility is that the induction of cell-cycle arrest by PTEN may be cell-type-dependent. Alternatively, differences in the mutational changes in different cancers may contribute in determining the cell-cycle phases. In fact, as demonstrated in the present study, overexpression of PTEN in colorectal cancers that are wtPTEN underwent G2 arrest while tumor cells that are mutant for PTEN underwent G1 arrest. Induction of G2 arrest by PTEN has also been observed in a broad spectrum of tumor cells of the prostate and melanoma that are wtPTEN, but not in tumor cells that are mutant or null for PTEN (Saito et al, unpublished data). These results indicate that the endogenous status of PTEN may play a role in the cellcycle arrest and warrants further investigation. Whatever the underlying mechanism, it is evident from the present study that the ability of PTEN to inhibit tumor growth is independent of the mutational status of PTEN in cancer cells and is in agreement with the findings previously reported by Li et al. 20 To further understand the mechanism by which PTEN induced G2/M arrest, G2/M-associated proteins were examined. In the G2/M phase, the active Cdc25C Inhibition of human colorectal cancer growth by PTEN Y Saito et al phosphatase dephosphorylates Cdc2 on both Thr 14 and Tyr 15, and then activates Cdc2/cyclin B1 complexes, leading to the progression of the cells to the M phase. However, in response to DNA damage or inhibition of DNA replication, the inhibitory phosphorylation of cdc2 still remains and the cells are arrested at the G2 phase. 31, [39] [40] [41] Our data demonstrated that Cdc25C was significantly downregulated, while cyclin B1 expression was upregulated following Ad-PTEN treatment in tumor cells compared to normal cells. Induction of G2/M arrest through inhibition of Cdc25C correlated with our cell-cycle analysis, where the number of tumor cells that underwent G2/M arrest was significantly higher than that in normal cells. Induction of G2/M arrest after Ad-PTEN treatment through inhibition of Cdc25C has also been observed in other tumor cell lines that are wtPTEN (unpublished data).
The mechanism by which PTEN suppressed cell growth and induced apoptosis appears to be dependent upon its phosphatase activity. Requirement of the PTEN phosphatase activity to downregulate the Akt, FAK, and p44/42MAPK pathways and activate the caspase-9 cascade has been previously demonstrated in tumor cells that are mutant or null for PTEN. 13, 14, [27] [28] [29] [30] [31] In agreement with these reports are the results from the present study. Treatment of colorectal cancer cells with Ad-PTEN resulted in the inhibition of Akt, FAK, and p44/42 MAPK pathways and activation of caspase-9 and -3. However, Ad-PTEN treatment in normal cells did not result in the regulation of these pathways, and may explain their inability to undergo apoptotic cell death, thereby achieving tumor-selective killing. The ability of tumor cells, but not normal cells that are wtPTEN, to undergo apoptotic cell death is in agreement with the findings of Li et al, 20 who demonstrated that colorectal tumor-bearing mice were divided into three groups (n¼9/group) and treated on alternate days for a total of six doses (3 Â 10 10 vp/dose) as follows: no treatment (m), Ad-Luc (E), and Ad-PTEN (T). Tumors were measured using calipers and the statistical significance of tumor volume changes was calculated using Student's t-test. Tumors treated with Ad-PTEN showed significant tumor inhibition (P¼0.01) compared to tumors that were not treated or treated with Ad-Luc. Each time point represents the mean tumor volume for each group. Bars represent standard error (SE). Finally, the ability of Ad-PTEN to suppress the growth of xenograft tumors (HT-29 and SW480) was investigated. Ad-PTEN treatment inhibited tumor growth significantly and supports our in vitro findings presented here. The ability of Ad-PTEN to inhibit human colorectal tumor growth that is wtPTEN has not been previously documented. In conclusion, the present study demonstrates the ability of Ad-PTEN to inhibit colorectal cancer growth, both in vitro and in vivo. Thus, adenovirusmediated transfer of the PTEN gene may be a promising therapeutic strategy for the treatment of patients with colorectal cancer.
Materials and methods

Cell lines and cultures
The colorectal cancer cell lines DLD-1, HT29, SW480, and Colo 320 HSR and the normal colon fibroblast cell line CCD-18Co were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). The cancer cell lines and normal cell line were maintained as recommended by ATCC. Cells were regularly passaged and tested for mycoplasma prior to use in the experiments.
Viral production and transduction efficiency
Construction and production of adenovirus carrying the PTEN (Ad-PTEN) and luciferase (Ad-Luc) gene have recently been described. 38 Prior to start of the experiment, transduction efficiency for the cell lines to be used was determined using an adenoviral vector carrying the green fluorescent protein (Ad-GFP). Treatment of cells with Ad-GFP different viral particle number per cell (vp/cell) demonstrated that more than 80% of the cells were transduced at 5000 vp/cell (data not shown). Therefore, in all subsequent experiments cells were treated with 5000 vp/cell.
Cell proliferation assay
All the cell lines were plated in six-well tissue culture plates at a density of 1 Â 10 5 cells/well. Tumor cells were then treated with Ad-PTEN or Ad-Luc, or treated with PBS as a mock control. Cells in each treatment group were plated in triplicate and cultured for 5 days. Then, at designated time points, cells were harvested by trypsinization and stained with 0.4% trypan blue (GIBCO BRL, Grand Island, NY, USA) to reveal dead cells. Viable cells were then counted using a hemocytometer.
Apoptotic staining
Cells were seeded in six-well tissue culture dishes at a density of 1 Â 10 5 cells/well and treated with Ad-PTEN or Ad-Luc. At 72 h after treatment, cells were analyzed for apoptosis using Hoechst 33258 staining (Sigma Chemicals, St Louis, MO, USA). Apoptotic cells were determined via apoptotic body and/or chromosome condensation.
Cell-cycle analysis
Cells were seeded in 10-cm culture dishes (5-10 Â 10 5 cells/dish) and treated with Ad-PTEN or Ad-Luc, or treated with PBS, 20-mM LY294002 (Cell Signaling Technology, Beverly, MA, USA) or 0.2% DMSO alone; LY294002 was reconstituted in DMSO. At specific times after treatment, cells were harvested via trypsinization, washed once with ice-cold PBS, fixed with 70% ethanol, and stored at À201C. Cells were then washed twice with ice-cold PBS and treated with RNase (30 min at 371C, 500 U/ml; Sigma Chemicals, St. Louis, MO, USA), and DNA was stained with propidium iodide (50 mg/ml; Boehringer Mannheim, Indianapolis, IN, USA). The cellcycle phase and apoptotic rate (cells at sub-G0/G1 phase) were analyzed using a FACScan (EPICS XL-MCL; Beckman Coulter Inc; Fullerton, CA, USA).
Immunoblot analysis
Cells were treated with Ad-PTEN or Ad-Luc, or treated with PBS, 20-mM LY294002, 10-mM U0126 (Cell Signaling Technology Inc., Beverly, MA, USA), or 0.2% DMSO alone. Cells were incubated for indicated number of hours at 371C and then collected to prepare whole-cell lysates as previously described. 38, 42 The following antibodies were used as primary antibodies: PTEN, Cdc25C, Cdc2, and Cyclin B1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); caspase-9, caspase-3, PARP, and phospho-FAK (Pharmingen, San Diego, CA, USA), b-actin (Sigma Chemicals, St Louis, MO, USA); p27
Kip1 , Akt, Phospho-Akt, phospho-FKHR, phospho-GSK3a/b, p44/42MAPK, and phospho-p44/42MAPK (Cell Signaling Technology Inc; Beverly, MA, USA). The proteins were visualized on an enhanced chemiluminescence (ECL) film (Hyperfilm, Amersham Biosciences, Inc., Piscataway, NJ, USA) using ECL Western blot detection reagent (Amersham Biosciences, Inc., Piscataway, NJ, USA).
In vivo tumor xenograft studies
Subcutaneous tumor xenografts (HT29 and SW480) were established in nude mice by injecting tumor cells (5 Â 10 5 cells/animal) in the right dorsal flank. When the tumor had reached a size of 50-100 mm 3 , animals were randomized into three groups (n¼9 animals/group) and treatment was initiated as follows: group 1 received no treatment; group 2 received Ad-Luc (3 Â 10 10 vp/ dose); and group 3 received Ad-PTEN (3 Â 10 10 vp/ dose); all treatments were given on alternate days for a total of six doses. Intratumoral injections were performed under anesthesia. Tumor measurements were recorded without knowledge of the treatment groups as previously described. 43 Experiments were terminated when tumors showed signs of necrosis. The therapeutic effect was determined by statistical analysis using Student's t-test.
